Trial Profile
A phase II trial to assess the activity of TroVax alone vs TroVax plus interferon alfa (IFN-alpha) on patients with advanced or metastatic renal cell cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA 5T4 (Primary) ; Interferon alpha
- Indications Renal cancer
- Focus Therapeutic Use
- 01 Jun 2009 Updated results presented at ASCO 2009.
- 24 Aug 2008 Status changed from active, no longer recruiting to completed.
- 16 May 2008 Data will be presented at ASCO 2008 according to a Oxford BioMedica media release.